Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD’s annual review of adverse events published
The number of safety (adverse reaction) reports increased in only two major species, dogs and sheep.

Report highlights rise in suspected lack of efficacy reports for cats

The Veterinary Medicines Directorate (VMD) has published its annual review of adverse events in animals, humans and the environment after the use of veterinary medicines.

The Veterinary Pharmacovigilance in the United Kingdom review summarises 6,721 UK adverse events reported to the VMD in 2017, an increase of 2.5 per cent on the previous year, compared to 15 per cent from 2015 to 2016.

Of the reports received, dogs were the only major species that had increased (9%). The largest decrease was for rabbits, with a fall of more than 31 per cent.

The report also highlights a considerable rise in the number of suspected lack of expected efficacy reports for cats compared to 2016. These were for products that affect the nervous system, including general anaesthetics, sedatives and analgesics.

Products for reversal of sedation also increased, as did combined treatments for the prevention of infestation by international and external parasites.

The number of safety (adverse reaction) reports increased in only two major species, dogs and sheep. The increase in dogs was owing to reports involving medicines for treating the intestines, heart and circulation, the nervous system and the ears.

Half of the products involved in sheep safety cases were anti-parasitics, with 50 per cent of those being wormers. 

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
RCVS annual renewal fee for vets due

RCVS' annual renewal fee for veterinary surgeons is now due. Vets must pay their renewal fee before Wednesday, 1 April 2026.

This year's standard annual fee has increased to 431 from last year's 418. This is an approximately three per cent increase, as approved by RCVS Council and the Privy Council.

Tshidi Gardner, RCVS treasurer, said: "The small fee increase will be used to help deliver both our everyday activities and our new ambitious Strategic Plan, which includes aims such as achieving new legislation, reviewing the Codes of Professional Conduct and supporting guidance, and continuing to support the professions through activities such as the Mind Matters Initiative, RCVS Academy and career development."

A full breakdown of the new fees is on the RCVS website. Information about tax relief is available on the UK government website.